Archives

20 February 2019 HALF-YEAR REPORT Pursuant to listing rule 4.2A, please find following Medical Developments International’s Consolidated Half-Year Report and associated results announcement, which should be read in conjunction with the most recent annual financial report. For a full copy of the Half-Year Report, please click on the following link:  MDI FY19 HY Report and Accounts

29 August 2018 ASX Announcement Penthrox: USA update Medical Developments International Limited (ASX: MVP) advise that it has received correspondence from the USA Food & Drug Administration (“FDA”) in relation to its Investigative New Drug (“IND”) application to have Penthrox approved for sale in the United States of America. For the full release, please click […]

17 August 2018 ASX Announcement Preliminary Final Report and Full Year Accounts   For the full report please click on the following link: Preliminary Final Report and Full Year Accounts

8 August 2018 ASX ANNOUNCEMENT Capital Raising – Placement and Share Purchase Plan  1. Placement Medical Developments International (ASX: MVP) (Company) is pleased to advise that it has today successfully secured a placement of 4,250,000 ordinary shares in the Company to a number of sophisticated and wholesale investors at a price of $4.00 per share, […]

For the full ASX Announcement “FY18 Results Update” please click on the following link: ASX Announcement – FY18 Results Update_060818

29 May 2018 ASX Announcement MVP signs exclusive Distribution Deal for Iran. Penthrox approved in Romania, Bulgaria, Slovenia & Cyprus. Medical Developments International Limited (ASX: MVP) is delighted to announce that it has concluded an exclusive Distribution Deal with Nikkan Pharma, part of the Darman Ara group of companies.  Darman Ara is one of Iran’s […]

14 May 2018 ASX Announcement Trading Update Medical Developments International Limited (ASX: MVP) CEO, Mr. John Sharman, warned today that despite the fact that during FY18 Penthrox has been approved for sale in 15 additional countries including Canada, Germany, Mexico, Sweden and numerous other European countries, the upside from this global expansion will not be […]

24 April 2018 ASX Announcement Penthrox approved in Finland Medical Developments International Limited (ASX: MVP) is delighted to announce that Penthrox has been approved for sale in Finland.   For the full release, please refer to the following link: Penthrox approved in Finland

10 April 2018 ASX Announcement Penthrox is approved in Canada Medical Developments International Limited (ASX:MVP), announce today that PENTHROX®, has been granted Market Authorisation in Canada. The Marketing Authorisation issued by Health Canada allows PENTHROX® to be used for the short-term relief of moderate to severe acute pain, associated with trauma or interventional medical procedures, […]

5 April 2018 ASX Announcement Penthrox approved in Germany Medical Developments International Limited (ASX: MVP) is delighted to announce that Penthrox has been approved for sale in Germany. MVP CEO, Mr. John Sharman said, “We are excited that the Marketing Authorisation for Germany has been received.  Germany is one of the most important markets for […]